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Abstract
Background. Elevated cystatin C in blood reﬂects impaired
glomerularﬁltrationrate(GFR),butcurrentcystatinCassays,
based on polyclonal antibodies and immunoturbidimetric
ornephelometricdetection,haveseverallimitations.Weeval-
uated a new immunoassay based on monoclonal antibodies
in samples from patients with and without chronic kidney
disease (CKD).
Methods. The study enrolled 170 men without known
CKD (Group A) and 104 men with CKD (Group B). All
patients were assessed with iohexol clearance, plasma
creatinine and plasma cystatin C by a conventional par-
ticle-enhanced immunoturbidimetric assay (PETIA) and
by the new double monoclonal assay. In Group A, three
serial blood draws were performed at median intervals of
4 h and 12 days between samples, to also allow assess-
ments of the variability in cystatin C values with the new
assay. Concordance correlation coefﬁcients and the 95%
limits of agreement were used to estimate the agreement
of reciprocal cystatin C and reciprocal creatinine with
iohexol clearance.
Results. Median iohexol clearance (mL/min/1.73 m
2)w a s
81 [interquartile range (IQR) 70, 92] in Group A and 23
(IQR 16, 34) in Group B. The concordance correlation
with GFR for the new cystatin C assay compared to the
established assay was similar in Group A (0.441 versus
0.465) but higher in Group B (0.680 versus 0.593). Cys-
tatin C measured by both assays exhibited closer agree-
ment with GFR than creatinine. The agreement between
the two cystatin C assays was high, with concordance
correlations of 0.815 in Group A and 0.935 in Group B.
Compared to the conventional assay, the new assay tended to
yield lower values of cystatin C at the low end of the range in
Group A. The new cystatin C assay exhibited small intra-
individual variability across serial samples (coefﬁcient of var-
iation  6%).
Conclusions. In this ﬁrst clinical evaluation, the new cystatin
C assay performed similarly to the established PETIA in
patients with normal GFR and better in patients with CKD.
Thenewassaymayofferanalternativetocurrentcommercial
assays to detect and monitor impaired kidney function.
Keywords: creatinine; cystatin C; glomerular ﬁltration rate; iohexol
clearance; renal function
Introduction
Assessment of kidney function is important in clinical
practice for determining overall health, selecting correct
dosages for drugs cleared by the kidneys, preparing for
therapeutic procedures and detecting acute and chronic
kidney disease (CKD). Assessment of kidney function is
also important because impaired kidney function is
strongly associated with cardiac diseases [1–3]. Epidemio-
logic studies have shown that CKD in many countries has a
prevalence of >10% [4] and that prevalence is rising [5].
However, the best index of kidney function, glomerular
ﬁltration rate (GFR), cannot be measured easily in clinical
practice. Indirect estimation of GFR from serum creatinine
has long been the only method practical for routine clinical
testing, but serum creatinine has several limitations. There-
fore, the recommended method for evaluating kidney func-
tion is to use the serum creatinine value in a formula that
estimates GFR.
Cystatin C has many characteristics of an ideal endoge-
nous GFR marker [6]. Several investigations have indi-
cated that serum cystatin C is as good as or better than
serum creatinine as a GFR marker in patients with native
kidneys, especially in patients with mild or moderate re-
duction of GFR [7–10]. In a meta-analysis, serum cystatin
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both in children and adults [7]. However, there are conﬂict-
ing results, and some investigators have not found cystatin
C to be advantageous [11]. One possible reason for con-
ﬂicting results on the relationship between GFR and cys-
tatin C is that factors other than GFR may affect serum
cystatin C levels [11–13]. Another possible reason is that
some of the studies used samples that had been stored for a
long period of time, which may have caused analytical
problems. Nevertheless, the promising results on estimat-
ing renal function from cystatin C have led to the develop-
ment of commercial assays, sold as reagent kits, which use
polyclonal antibodies against cystatin C. Signal detection is
based on light scattering in particle-enhanced turbidimetric
and nephelometric immunoassays (PETIA and PENIA, re-
spectively). However, the use of polyclonal antibodies can
cause variation from batch to batch. In addition, the use of
light scattering can render the assay susceptible to interfer-
ing factors such as lipemia, hemolysis and bilirubinemia.
This interference is recognized on turbidimetric detection
principles. Samples that have been stored may have other
drawbacks in turbidimetric assays, such as opalescence
from precipitated lipids.
A newly designed assay for cystatin C based on two
monoclonal antibodies and time-resolved ﬂuorescent de-
tection [14] is potentially less prone to these forms of
interference. The use of monoclonal instead of polyclo-
nal antibodies makes the assay more uniform and stable.
The monoclonal antibody combination in the new assay
gives fast binding and good correlation (R ¼ 0.949) with
a PETIA assay from Roche (Basel, Switzerland). The
new assay also demonstrates excellent linearity and a
wide linear range in measuring cystatin C concentra-
tions, covering all clinically relevant concentrations of
cystatin C, and the assay measures highly similar con-
centrations of cystatin C in serum samples compared to
anticoagulated plasma samples [14]. The imprecision of
the new assay is also suggested to be low with a total
imprecision of <5.6% [14]. The new assay for cystatin C
is sensitive and therefore uses extensive sample dilution,
which diminishes possible interference from the sample,
particularly interference caused by heterophilic antibod-
ies. In addition, a wash step prior to detection in the new
assay removes blood components that could potentially
interfere with signal detection.
The aim of this study was to evaluate the performance of
the new assay in patients with normal and reduced kidney
function. Results of new and established cystatin C assays
and creatinine assays were compared to plasma clearance
of iohexol, which we considered the gold standard for as-
sessment of GFR.
Materials and methods
Patients and blood collection
Two groups of patients were used in these analyses: those with normal
renal function (Group A) and those with slight to advanced renal dysfunc-
tion (Group B). Group A consisted of 220 consecutive male patients with-
out known renal disease seen at the Department of Urology, Skåne
University Hospital, Sweden, during October 2001 and April 2004. Those
missing data for iohexol clearance (n ¼ 7), cystatin C (n ¼ 9) or creatinine
(n ¼ 34) were excluded, leaving 170 patients in Group A available for
analysis. In this group, we collected three blood samples for analysis of
variability. The median interval between Time 1 (before measurement of
iohexol clearance) and Time 2 (immediately after iohexol clearance) was 4
h (range: 3–7 h); the median interval between Time 1 and Time 3 was 12
days (range: 6–38 days). The samples from Times 2 and 3 were used only
in the variability analysis.
GroupBconsistedof108patientswithCKDenrolledattheDepartmentof
Nephrology and Transplantation, Skåne University Hospital, Sweden. Dur-
ing 2004 and 2006, at routine visits for GFR determination with iohexol
clearance, consecutive men were invited to participate in the study, and all
accepted the invitation. Those missing data for iohexol clearance (n ¼ 1) or
cystatin C (n ¼ 3) were excluded, leaving 104 patients in Group B available
foranalysis.Theincludedmenhadbeendiagnosedwithdiabeticnephropathy
(n ¼ 21), glomerulonephritis (n ¼ 22), non-speciﬁed renal disease (n ¼ 14),
nephrosclerosis(n¼15),oragroupofmiscellaneousrenaldiseases(n¼10),
or had renal transplants with stable but reduced renal function (n ¼ 22).
Blood was collected by venipuncture, centrifuged within <1 h at 3500
g for 10 min and then immediately stored at  80 C pending analysis.
Laboratory methods
Creatinine. Plasma creatinine was determined by a creatininase-based
procedure using the Hitachi Modular P analysis system (application 652;
Roche). The total analytical (intra-assay 1 inter-assay) imprecision was
3.0% for a control sample at a concentration of 60 lmol/L and 1.4% for a
control sample at 578 lmol/L. Reference range for men: 60–100 lmol/L.
Cystatin C, conventional assay. Plasma cystatin C was measured by a
fully automated PETIA [15]. The reagents were obtained from DAKO
(Dako A/S, Glostrup, Denmark) and the determination was performed
on the Hitachi Modular P analysis system. The total analytical imprecision
was 2.1% for a control sample at a concentration of 1.0 mg/L and 1.7% for
a control sample at 4.0 mg/L. Reference range: 0.55–1.15 mg/L for age 1–
50 years and 0.63–1.44 mg/L for age >50 years [16].
Cystatin C, new assay. Cystatin C concentration of plasma samples was
measured with an investigational immunoassay that uses monoclonal anti-
bodies (HyTest, Turku, Finland) for both capture and detection and is
based on time-resolved ﬂuorometry [14]. The assay has a wash step prior
to ﬂuorescence measurement and it is performed in all-in-one dry reagent
wells, which contain all required assay components, on an automated Aio!
Immunoanalyzer (Innotrac Diagnostics, Turku, Finland). One hundred-
fold dilution of plasma samples is used and the assay range covers un-
diluted cystatin C concentrations from 0.1 to 20 mg/L. The bias compared
to the conventional assay was 20% on average. The intra-assay impreci-
sion percentages for the new method were 4.6 and 2.8, the inter-assay
imprecision percentages 1.9 and 3.2 and the total assay imprecision per-
centages 4.6 and 5.5 at 0.8 mg/L and 3.2 mg/L, respectively [14].
Measured GFR (iohexol clearance). GFR was determined by measuring
the plasma clearance of iohexol according to a one-compartment model,
where samples were taken after the distribution phase, in the assumed
monoexponential part of the plasma decay curve. Iohexol was analyzed
by high-performance liquid chromatography technique [17, 18].
Statistical methods
To facilitate comparisons between cystatin C, creatinine and iohexol meas-
urements, we used 1/cystatin C (L/10
 1 g) and 1/creatinine (L/10
 2 mol).
These conversions were used for all analyses and in all ﬁgures. Iohexol
clearance (mL/min/1.73 m
2) was considered the true GFR (gold standard).
To quantify the amount by which values of 1/cystatin C and 1/creatinine
differed from GFR, we calculated the concordance correlation coefﬁcient
and the 95% limits of agreement. The concordance correlation coefﬁcient
combines measures of both precision and accuracy to determine how far the
observeddatadeviatefromthelineofperfectconcordance(i.e.thelineat45 
on a square scatter plot). The 95% limits of agreement represent the region
within which 95% of the differences between measurements are expected to
lie.Forillustrativepurposes,wecreatedscatterplotsofallpatients’reciprocal
cystatinCorcreatinineandGFRmeasurements.Todescribethevariabilityof
cystatin C across the three time points, we calculated the intraindividual
coefﬁcients of variation. These coefﬁcients of variation were calculated as
the ratioofthestandard deviationto themean withineachindividualand are
expressed as percentages. All analyses were conducted separately by cohort
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analyses were conducted using Stata 10.0 (StataCorp, College Station, TX).
Ethical considerations
The study was approved by the regional ethics committee at Lund University,
Sweden, LU 587-00, and all subjects provided written consent to participate
in the study and to allow retrieval of information from medical records.
Results
Patient characteristics and renal function measurements for
the two groups are shown in Table 1. Median age was 65
years in Group A (patients without known CKD) and 57
years Group B (patients with CKD). Overall, cystatin C
measurements were lower and more homogenous in Group
A than in Group B. Iohexol clearance measurement showed
a median GFR of 81 [range of 29–119, interquartile range
(IQR) 70–92] mL/min/1.73 m
2 in Group A. This ‘normal
renal function’group included49participants (29%) withno
CKDorStage1CKD,104(61%)withStage2,16(9%)with
Stage 3 and 1 (0.6%) with Stage 4. InGroup B, median GFR
measured from iohexol clearance was signiﬁcantly lower at
23 (range 8–83, IQR 16–34) mL/min/1.73 m
2.I nt h i sg r o u p ,
four patients (4%) had Stage 2 CKD, 29 (28%) had Stage 3
CKD, 51 (49%) had Stage 4 and 20 (19%) had Stage 5.
Table 1. Summary of patient characteristics
a
Group A (normal renal function), N ¼ 170 Group B (CKD), N ¼ 104
Age (years) 65 (60, 71) 57 (47, 70)
Creatinine (lmol/L) 78 (70, 85) 224 (160, 295)
Conventional cystatin C (mg/L) 1.08 (1.01, 1.16) 2.63 (2.11, 3.40)
New cystatin C (mg/L) 1.03 (0.910, 1.14) 2.42 (1.91, 3.02)
Iohexol clearance (mL/min/1.73 m
2) 81 (70, 92) 23 (16, 34)
aAll values are median (IQR).
Table 2. Agreement of reciprocal creatinine and cystatin C values with measured GFR
a
Group A (normal renal function) Group B (renal disease)
Median
(IQR)
Concordance
correlation
coefﬁcient
Average
difference (95%
limits of
agreement)
Median
(IQR)
Concordance
correlation
coefﬁcient
Average difference (95%
limits of
agreement)
1/Creatinine (L/10
 2 mol) 128 (118, 143) 0.161 49.9 (16.5, 83.2) 45 (34, 63) 0.499 21.2 (0.1, 42.2)
1/Conventional cystatin C assay (L/10
 1 g) 93 (86, 99) 0.465 11.6 ( 12.6, 35.8) 41 (33, 52) 0.593 16.8 (4.4, 29.3)
1/New cystatin C assay (L/10
 1 g) 97 (88, 110) 0.441 17.1 ( 10.8, 45.1) 38 (29, 48) 0.680 13.1 (0.9, 25.3)
aAverage difference is the eGFR—true GFR (iohexol clearance).
Fig. 1. Calibration plot of 1/cystatin C values from the conventional assay
as compared to iohexol clearance (gold standard). The black line repre-
sents perfect agreement. Patients with CKD (Group B) are represented by
solid circles; patients without diagnosis of kidney disease (Group A) are
represented by hollow circles.
Fig. 2. Calibration plot of 1/cystatin C values from the new assay as
compared to iohexol clearance (gold standard). The black line represents
perfect agreement. Patients with CKD (Group B) are represented by solid
circles; patients without diagnosis of kidney disease (Group A) are repre-
sented by hollow circles.
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ﬁcients and limits of agreement for 1/cystatin C and 1/
creatinine compared to iohexol clearance. Overall, the
agreement between cystatin C and the true GFR was
higher in patients with renal disease (Group B) than in
those with normal renal function (Group A). When the
two cystatin C assays were compared with iohexol clear-
ance in Group A, the conventional assay had a slightly
higher concordance correlation than the new assay,
whereas in Group B, the new assay had the higher con-
cordance correlation. Both cystatin C assays tended to
overestimate true GFR in both cohorts (Figures 1 and 2,
Table 2), but both cystatin C assays exhibited better
agreement with iohexol clearance than did creatinine in
Group A and B (Figures 1–3). The lowest concordance
correlation was shown between 1/creatinine and iohexol
clearance. However, at low levels of renal function (GFR
< 30), creatinine appeared to have better agreement with
GFR (Figure 3).
Figure 4 shows the correlation plots for reciprocal
plasma cystatin C values determined with the conven-
tional and new cystatin C assays. The agreement between
the two assays for cystatin C was high, with concordance
correlation 0.815 in Group A and 0.935 in Group B. The
new assay, compared to the conventional assay, tended
to yield slightly higher values at the high end of 1/cys-
tatin C (Figure 4). The increasing difference between the
two methods for cystatin C at higher GFR is also seen in
Bland Altman plots for Groups A and B (Figure 5a and b,
respectively).
We summarized the variation of reciprocal cystatin C
levels across different time points as the coefﬁcient of var-
iation measured with the new assay using serial blood sam-
ples obtained at three separate time points from the men in
Group A (Table 3). The intraindividual coefﬁcients of var-
iation between the time points were low and relatively
consistent. The mean (SD) variation in cystatin C as well
as in reciprocal cystatin C was 6% (4%) between Time 1
and 3 and was 5% (4%) both between Time 1 and Time 2
and between Time 2 and Time 3.
Fig. 3. Calibration plot of 1/creatinine as compared to iohexol clearance
(gold standard). The black line represents perfect agreement. Patients with
CKD(GroupB)arerepresentedby solidcircles;patientswithoutdiagnosis
of kidney disease (Group A) are represented by hollow circles.
Fig. 4. Calibration plot of conventional cystatin C assay as compared to the
new cystatin C assay. The black line at 45  represents perfect agreement.
Patients withCKD (GroupB) arerepresentedbysolidcircles;patientswithout
diagnosis of kidney disease (Group A) are represented by hollow circles.
Fig. 5. Bland Altman plots for the two measures of cystatin C, (a) for
Group A and (b) for Group B. The x-axis is the average of the two 1/
cystatin C measures and the y-axis is the difference (conventional meth-
od—new method). The horizontal lines represent the average difference
and the 95% limits of agreement.
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Many studies have shown advantages of cystatin C over
creatinine as a GFR marker. Although some studies have
not shown such an advantage, almost none have shown
better diagnostic performance for creatinine than for cys-
tatin C. However, the established cystatin C assays have
some methodologic weaknesses, such as susceptibility to
interference from substances in blood, especially in sam-
ples that have been stored. Some of these methodologic
weaknesses of the standard cystatin C assays are addressed
by a recently developed highly sensitive assay for plasma
cystatin C that uses two monoclonal antibodies [14], and
the current report is the ﬁrst clinical evaluation of this new
assay. Here, we demonstrate that this new assay performs
well compared to the conventional PETIA. In particular,
we have demonstrated that the new assay performs better
than the old assay in male patients with CKD. Cystatin C,
with both assays, is superior to creatinine in correlation
with iohexol clearance.
From our ﬁndings, that reciprocal cystatin C levels ex-
hibited much better agreement with true GFR than recip-
rocal creatinine levels, we anticipate that subsequent
development and use of an estimated glomerular ﬁltration
rate (eGFR) formula that is based on cystatin C, or possibly
could incorporate both creatinine and cystatin C, would
substantially improve the agreement with measured GFR.
However, we did not use the published cystatin C-based
eGFR formula, which was developed for use with the
conventional assay [19], as the accuracy of the cystatin
C-based eGFR formula would be biased in favor of the
conventional assay and would not permit a fair comparison
with the new cystatin C assay.
The concordance correlation coefﬁcient with measured
GFR was higher in the group of men with impaired renal
function for all assessments, both cystatin C assays and
creatinine. The reason for this is not completely clear, but
formulas for eGFR also perform better in decreased GFR
ranges than in the normal range [20]. It is well known that
eGFR calculated by the modiﬁcation of diet in renal disease
formula underestimates GFR in the normal range by up to
30% but only by 6% in patients with CKD.
With the new cystatin C assay, intraindividual varia-
bility between time points, described as coefﬁcients of
variation, was found to be small and clinically insignif-
icant. This low short-term variability reﬂects not only the
stability of the new assay as a diagnostic test and
strengthens the precision, reliability and clinical utility
of cystatin C as a GFR marker but also suggests strongly
that the intraindividual variation in cystatin C levels in
blood among subjects with normal or only moderately
impaired GFR is very small. Although the analytical im-
precision of the new method is higher than that of the
conventional method, the measured intraindividual var-
iation, which sets the actual variability of the test results,
was higher than the imprecision of the new cystatin C
method.
In this study, the established cystatin C assay used for
comparison was a PETIA. A recent investigation has
suggested that PENIA may be more reliable than PETIA
[21], which could limit the conclusion of our study. How-
ever, numerous studies with PETIA have shown a good
correlation with GFR measured by standard methods [7,
22], and we also had true GFR values included in this
study. Nevertheless, our results need to be conﬁrmed in
relation to a PENIA. Another possible limitation in com-
parative studies is that the conventional assays for cysta-
tin C are not standardized. The lack of an international
calibrator complicates the estimation of agreement of
cystatin C values with true GFR since systematic differ-
ences in cystatin C levels between different assay tech-
nologies are known to exist and were seen in this study,
especially at high levels of cystatin C. The difference
between the conventional and the new method is interest-
ing, and it actually seems that compared to the iohexol
GFR values, 1/cystatin C measured with the new assay
shows a higher parallelism to the line of identity than
does 1/cystatin C measured with the conventional assay.
The nonlinear association between the cystatin C assays
could be related to the fact that the linear range of the
conventional method is narrower compared to other com-
mercial cystatin C methods.
A strength of our study is the wide range of GFR en-
compassed by the study groups with and without known
CKD. It is both a strength and limitation in our study that
we assessed male patients only. The advantage of examin-
ing renal function according to sex is that we do not have to
account for known differences in creatinine between males
and females. However, as a limitation, these results need to
be conﬁrmed in a female population, which is a future
project of ours. If similar data showing high concordance
correlation between the new cystatin C assay and iohexol
clearance can be replicated also in women, it would be
appropriate to develop a formula for eGFR based on this
new cystatin C assay. The ongoing development of an
international calibrator will further strengthen cystatin C
as a GFR marker.
Conclusion
In this ﬁrst clinical evaluation, the new assay for cystatin C
shows good agreement with the established conventional
PETIA. In patients with CKD, it showed better agreement
with true GFR than PETIA. These results imply that the
new assay may be an alternative to the present commercial
assays.
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